Shire completes $2.4bn oncology sale to Servier
31st Aug 2018 09:07
(Sharecast News) - Shire has completed the sale of its oncology franchise to Servier for $2.4bn, it announced on Friday.
Read moreFDA gives nod to Shire's TAKHZYRO treatment
24th Aug 2018 08:06
(Sharecast News) - Shire announced on Friday that, following priority review, the US Food and Drug Administration (FDA) has approved the 'TAKHZYRO' (lanadelumab-flyo) injection for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Read moreShire and Shionogi apply to expand ADHD treatment to adults
13th Aug 2018 07:51
(Sharecast News) - Shire and Shionogi have applied to expand the use in Japan of co-developed drug Intuniv to treat adults for attention deficit hyperactivity disorder.
Read moreShire's quarterly sales rise on immunology demand
31st Jul 2018 12:08
(Sharecast News) - Shire reported healthy sales growth in the second quarter as the biotech company pressed ahead with its acquisition by Takeda of Japan.
Read moreLondon close: FTSE mixed as Unilever flies after rebuffed Kraft Heinz bid
17th Feb 2017 17:15
(ShareCast News) - London stocks closed mixed after a Friday session that saw blue-chip consumer goods giant Unilever fly higher after it slapped away a $143bn offer from Kraft Heinz, which has indicated it will return to the table. The rebuffed offer -- $50 a share in a mix of cash and shares -- wa
Read moreShire earnings beat estimates and remains 'extremely optimistic' for 2017
16th Feb 2017 12:30
(ShareCast News) - Shire has reported fourth quarter sales and earnings that beat City estimates, with the drugmaker confident of generating strong top- and bottom-line growth in 2017. Revenues for the quarter came in £3.81bn, versus the consensus $3.77bn, while earnings per share of $3.37 beat the
Read moreSector movers: Cyclicals bounce back, Evraz in the lead
1st Feb 2017 15:46
(ShareCast News) - There was a clear split in the market on Wednesday as cyclicals bounced back and the more defensive segments of the market were relegated to the bottom of the pile. Thus, shares in Prudential and Aviva were to be seen pacing gains among life insurers as yields on benchmark 10-year
Read moreFTSE 100 movers: Pharmaceutical stocks lead FTSE's rally
16th Dec 2016 14:11
(ShareCast News) - The FTSE 100 rose 0.11% to 7,006.73 points on Friday afternoon with pharmaceutical stocks leading the way. Hikma Pharmaceuticals, Shire and Astrazeneca rallied on a positive read-across following reports Sanofi is in advanced talks to acquire Actelion. The companies are said to b
Read moreBroker tips: Shire, GKN, IG Group
7th Dec 2016 15:08
(ShareCast News) - UBS downgraded Shire to 'neutral' from 'buy' and cut the price target to 5,000p from 5,600p saying a tougher environment for expensive orphan drugs was likely to constrain performance. This, and other issues such as low return on invested capital and the 2023 Vyvanse patent expiry
Read moreUBS downgrades Shire on orphan drug concerns
7th Dec 2016 14:03
(ShareCast News) - UBS downgraded Shire to 'neutral' from 'buy' and cut the price target to 5,000p from 5,600p saying a tougher environment for expensive orphan drugs was likely to constrain performance. This, and other issues such as low return on invested capital and the 2023 Vyvanse patent expiry
Read morePharma stocks to outperform versus Miners as US dollar gains, Deutsche Bank says
1st Dec 2016 09:42
(ShareCast News) - Pharmaceuticals' recent underperformance versus Mining stocks might be set to end, strategists at Deutsche Bank said. The approximately 5% gain in the US dollar index over the past three months would have been consistent with double-digit outperformance by the former, the investme
Read moreShire to build innovation hub in Massachusetts
22nd Nov 2016 17:01
(ShareCast News) - Irish pharmaceutical company Shire announced that it will expand its operations in Cambridge, Massachusetts through the establishment of an innovation hub to study rare diseases. Shire and BioMed Realty have signed a lease for a 343,00 square foot building at 500 Kendall street ca
Read moreFriday broker round-up
11th Nov 2016 09:55
(ShareCast News) - Imperial Brands: JP Morgan keeps at neutral with a target price of 3660p. Standard Life: Berenberg stays at buy 416p target. Barclays: Societe Generale upgrades to buy with a 235p target. UBM: Barlcays reiterates equal-weight with a 755p target. Derwent London: Goldman Sachs ke
Read moreSector movers: Miners, US election-related plays lead gains
9th Nov 2016 15:17
(ShareCast News) - Steel and mining stocks led gains for another session, amid widespread gains for most base metals and coal, helped by an initial bout of weakness in the US dollar. As of 1650 GMT, the US dollar was trading higher by 0.47% to 98.32 points after having earlier hit an intra-day low a
Read moreAnalysts pick winners as pharma sector bounces back on Clinton loss
9th Nov 2016 13:58
(ShareCast News) - The pharmaceuticals sector bounced back after Donald Trump won the battle to become the next president of the United States and the Republican party won control of Congress, with analysts suggesting AstraZeneca, Shire and Eli Lilly were among the best placed stocks to capitalise o
Read more